Reaction

Product Administered To Patient Of Inappropriate Age reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 5,930 reports · 127 co-occurring drugs

As of the last recalculation, Product Administered To Patient Of Inappropriate Age appears in 5,930 FAERS reports alongside 127 co-occurring drug terms. The strongest observed disproportionality signal is PROPRANOLOL HYDROCHLORIDE (PRR 70.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Propranolol Hydrochloride1,16970.771.8
Cetirizine Hydrochloride Allergy38347.448.0
Cetirizine Hydrochloride Tablets38347.448.0
Instalax Polyethylene Glycol 33508725.025.1
Polyethylene Glycol 4008724.424.6
Amikacin10421.821.9
Cetirizine38918.818.9
Bupivacaine4918.618.6
Fexofenadine6814.614.7
Busulfan6314.214.2
Posaconazole6414.014.0
Posaconazole Delayed-Release3912.512.6
Methimazole2712.112.2
Cannabidiol7611.511.6
Guanfacine2410.710.8
Cetirizine Hydrochloride43810.010.0
Fexofenadine Hcl269.99.9
Sirolimus379.79.7
Fludarabine Phosphate1039.39.4
Temozolomide549.19.1
Abaloparatide759.09.1
Brexpiprazole428.99.0
Ibuprofen5617.97.9
Rocuronium Bromide267.87.8
Acetylcysteine197.17.1
Sevoflurane166.86.8
Clobazam466.76.7
Ganciclovir196.56.5
Ganciclovir Sodium196.36.3
Micafungin Sodium156.26.2
Fexofenadine Hydrochloride386.26.2
Midazolam Hydrochloride476.26.2
Polyethylene Glycol 33501626.16.1
Tretinoin146.16.1
Pseudoephedrine Hydrochloride175.85.8
Vortioxetine285.85.8
Midazolam415.75.7
Ibuprofen And Diphenhydramine Citrate365.55.5
Selexipag344.64.6
Thiotepa124.44.4
Ibuprofen Capsule2424.44.4
Ibuprofen Tablet, Film Coated2424.44.4
Ibupfrofen2424.44.4
Ibuprofen Tablets Usp, 200Mg2424.44.4
Ibuprofen Oral2424.44.4
Ibuprofen Capsules 200 Mg2424.44.4
Ibuprofen 200 Mg2424.44.4
Ibuprofen 200Mg2424.44.4
Escitalopram Oxalate894.34.3
Valganciclovir234.34.3
Valganciclovir Hydrochloride234.34.3
Alemtuzumab234.24.2
Amphotericin B143.93.9
Aripiprazole Oral463.93.9
Aripiprazole Orally Disintegrating463.93.9
Basiliximab133.93.9
Primidone113.83.8
Melatonin573.73.7
Ciclesonide143.63.6
Mometasone Furoate And Formoterol Fumarate Dihydrate163.63.6
Diclofenac Potassium113.63.6
Zonisamide153.63.6
Sorafenib213.63.6
Palivizumab153.43.4
Nemolizumab-Ilto123.33.3
Propofol343.33.3
Sotalol Hydrochloride153.23.2
Naproxen Sodium Tablet, Coated123.13.1
Naproxen Sodium, Coated Tablets123.13.1
Naproxen Sodium 220Mg123.13.1
Ursosiol173.13.1
Fluticasone Furoate102.92.9
Doxyclycline Hyclate142.92.9
Mometasone Furoate342.92.9
Aripiprazole992.92.9
Lurasidone Hydrochloride172.92.9
Meropenem262.92.9
Fluticasone Propionate And Salmeterol Xinafoate482.82.8
Ursodiol172.72.7
Suvorexant102.72.7
Escitalopram1062.72.7
Escitslopram442.72.7
Phenobarbital112.72.7
Tamsulosin Hydrochloride152.62.6
Mycophenolate Mofetil Hydrochloride972.52.5
Everolimus Tablets122.52.5
Mycophenolate Mofetil962.52.5
Vigabatrin102.42.4
Tobramycin162.32.3
Trametinib162.32.3
Ruxolitinib472.32.3
Vilazodone Hydrochloride62.32.3
Voriconazole Injection142.32.3
Tolvaptan92.22.2
Vedolizumab532.22.2
Tacrolimus Ointment 0.1%762.22.2
Tacrolimus Extended-Release Capsules762.22.2
Regorafenib72.12.1
Granisetron62.02.0
Canakinumab61.91.9
Tadalafil521.81.8
Amphetamine41.71.7
Botulinum Toxin Type A61.71.7
Fluticasone Furoate And Vilanterol Trifenatate171.71.7
Dupilumab2201.61.6
Etonogestrel221.61.6
Dornase Alfa91.61.6
Lisdexamfetamine Dimesylate151.61.6
Levetiracetam In Sodium Chloride351.61.6
Levetiracetam Oral351.61.6
Levetiracetam Injection351.61.6
Cariprazine41.51.5
Brentuximab Vedotin41.41.4
Irinotecan Hydrochloride51.41.4
Methylphenidate111.31.3
Ambrisentan461.31.3
Glycerin, Lidocaine51.31.3
Fremanezumab-Vfrm41.21.2
Docosanol51.21.2
Azacitidine For61.21.2
Elexacaftor, Tezacaftor, And Ivacaftor41.11.1
Minoxidil131.01.0
Pseudoephedrine Hcl31.01.0
Minoxidil Foam 5% (Womens)80.90.9
Paliperidone Palmitate60.70.7
Adapalene190.40.4
Salicylic Acid50.30.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.